Nodality Inc., an innovative biotechnology company advancing discovery, development and use of transformative therapies by revealing functional systems biology, announced promising data utilizing the company’s proprietary Single Cell Network Profiling (SCNP) technology in metastatic melanoma. Nodality’s SCNP technology reveals functional biology underlying the most important and intractable diseases, providing critical insights to help guide the discovery and development of next-generation therapeutic agents. According to data published in the current issue of the Journal of Translational Medicine (JTM), Nodality’s researchers have identified key biomarkers in the blood that can help predict responses to new therapies for melanoma, including cancer immunotherapeutics.“While there has been exciting recent progress in the treatment of melanoma, new therapies have been found to benefit only a subset of patients and are often associated with significant adverse effects,” commented Laura Brege, Nodality’s president and CEO. “With our highly sensitive and reproducible SCNP platform, we are able to attain a deep, functional understanding of how the immune system behaves in the presence of tumor cells and how cancer cells vary in their response to approved and promising development-stage therapies. In light of SCNP’s broad range of capabilities and potential applications, we believe our technology can play an essential role in advancing pipelines of targets and therapeutics to deliver the next generation of drugs for cancer and other major illnesses.”
Date: May 28, 2014
Source: Nodality
